PubMed HealthSearch

Biomedical subjects

Jin Kang

Publications and source records attributed to Jin Kang.

2 recordsLinked to original sources

Histone H3K27ac spreads from enriched chromatin domains into neighboring regions upon loss of CTCF binding.

Acetylation of histone H3 at lysine 27 (H3K27ac) is enriched at enhancers and highly transcribed genes. Our previous study showed that an H3K27ac-enriched chromatin domain expanded into neighboring regions following the deletion of CTCF-binding motifs flanking the domain. In this study, we explored the spreading of H3K27ac on a genome-wide scale by analyzing its distribution around CTCF-binding sites in human K562 cells and examining changes upon CTCF loss. We found that a subset of CTCF-binding sites demarcates H3K27ac-enriched domains. Upon loss of CTCF binding, H3K27ac levels increased in most regions adjacent to these domains, indicating that H3K27ac can spread into neighboring chromatin. This spreading was accompanied by elevated transcription of nearby genes. Chromatin features, including histone modifications, CTCF-binding intensity, and CTCF-mediated chromatin interactions, were associated with the H3K27ac spreading. Notably, enhancers were more enriched within domains that exhibited H3K27ac spreading compared to those that did not, and the deletion of enhancers from the CTCF motif-deficient β-globin locus attenuated the spreading. These findings indicate that CTCF-binding sites serve as boundaries for H3K27ac-enriched domains and that, in the absence of CTCF binding, H3K27ac can spread into neighboring regions. H3K27ac spreading appears to be influenced by multiple chromatin features and to contribute to the transcriptional increase of nearby genes.

CTCF

Advancing cancer detection and treatment using longitudinal routine clinical data.

Cancer management remains fragmented across its continuum, from late-stage diagnosis and salvage therapies to non-personalized surveillance. Here, we present Oncoformer, a unified multimodal transformer model trained on the China Oncology Multimodal Prediction and Surveillance Study (COMPASS) cohort (3.67 million individuals, 17.7 million clinical visits) and validated on independent external cohorts, including the UK Biobank. Oncoformer integrates longitudinal electronic health records with chest X-ray imaging to address multiple clinical tasks: pan-cancer diagnosis (area under the receiver operating characteristic curve [AUROC] = 0.956), future cancer prediction up to 1 year before diagnosis (AUROC = 0.869), tumor stage inference (mean AUROC > 0.90), patient-specific treatment-response forecasting, and recurrence-free survival stratification across ten cancer types (all p < 0.01). Staging predictions were independently validated against postoperative pathological endpoints and shown to converge on core cancer genomic pathways. By translating routine clinical data into a dynamic view of cancer evolution, Oncoformer provides a framework for risk-informed cancer prediction and treatment stratification using routine clinical data.

Humans